Teijin (3401) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
13 Jun, 2025Executive summary
Revenue for FY2024 1H increased by 7.5% year-over-year to ¥507.5 billion, driven by Materials and Fibers & Products Converting segments.
Adjusted operating income rose 62.7% year-over-year to ¥18.6 billion, reflecting profitability improvements in composites and higher resin & plastic processing sales.
Net loss attributable to owners of parent was ¥53.4 billion, mainly due to a large impairment loss in North American composites.
Voluntary adoption of IFRS from FY2024, with adjusted operating income as a new key metric and prior periods restated.
Financial highlights
FY2024 1H revenue: ¥507.5 billion (+7.5% YoY); adjusted operating income: ¥18.6 billion (+62.7% YoY).
EBITDA for 1H: ¥55.6 billion (+11.8% YoY); ROIC improved to 3.3% from 1.8%.
Operating income fell to ¥-47.7 billion due to non-recurring impairment losses.
Cash and cash equivalents at period end were ¥110.1 billion, down from ¥123.2 billion at March 31, 2024.
Free cash flow for 1H: ¥-7.5 billion; net cash provided by operating activities was ¥23.2 billion, while investing activities used ¥30.7 billion.
Outlook and guidance
FY2024 revenue forecast: ¥1,010.0 billion (+5.2% YoY); adjusted operating income: ¥28.0 billion (+27.5% YoY).
Profit attributable to owners of parent forecast at ¥25.0 billion, reversing prior year loss; basic EPS of ¥129.78.
Annual dividend forecast raised to ¥50/share (from ¥30/share in FY2023).
Free cash flow projected at ¥140.0 billion for FY2024.
D/E ratio expected to improve to 1.0 by year-end.
Latest events from Teijin
- Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation27 Feb 2026 - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 202623 Feb 2026 - Profit and revenue growth offset healthcare headwinds, with rare disease and home care focus.3401
Q3 202523 Dec 2025 - Growth centers on high-value, sustainable solutions and global market expansion.3401
Investor Day 202519 Dec 2025 - Major impairment and business transfer drive net loss; outlook cut, dividend steady.3401
Q2 20261 Dec 2025 - FY2024 saw profit recovery and portfolio transformation; higher FY2025 income expected.3401
Q4 202520 Nov 2025 - Profits and revenue fell in Q1 FY2025, but full-year outlook and dividend remain steady.3401
Q1 20265 Aug 2025 - Teijin accelerates healthcare growth with a focus on rare diseases, home care, and innovation.3401
Investor Update13 Jun 2025 - Q1 FY2024 revenue and profit surged, with IT business divestiture and IFRS adoption underway.3401
Q1 202513 Jun 2025